Pharmaceutical Executive-09-01-2016

Pharmaceutical Executive

Pharm Exec’s 9th annual list of rising industry leaders illustrates how the deployment of essential human capital has changed in line with a business model that is no longer static and predictable-or complacent.

Pharmaceutical Executive

Pharm Exec sits down with UBC President Patrick Lindsay to provide some real-world context around our 2016 feature profile of sixteen Emerging Leaders in biopharma.

Pharmaceutical Executive

Pharm Exec and inVentiv Health convened a roundtable discussion at the 2016 ASCO meeting to review the use of patient-reported outcomes (PRO) in the clinical trial and commercialization space.

Pharmaceutical Executive

As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.

Pharmaceutical Executive
From the Editor

September 07, 2016

Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks-a realization that has slowly creeped into their business planning.

Pharmaceutical Executive

Traditional sales and pricing practices face legal challenges and political backlash.

Pharmaceutical Executive
Special Sponsored Section

September 01, 2016

A new campaign in France hopes to build on the nation’s legacy as a life sciences innovator, through championing a fresh pathway to success in areas such as preventative healthcare, advanced diagnostics, medical devices, home care, and big data.

Issue PDF
Pharmaceutical Executive

September 01, 2016

Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.